• Worked with the Irish NHS to secure patient access and greater healthcare provider choice by listing generic glatiramer acetate, a non-biological complex drug licensed for the treatment of relapsing forms of multiple sclerosis (MS), as the best value option through its Medicines Management Programme (MMP).